On September 22, 2025 Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, reported that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, honoring it as one of the most innovative and promising private biotechnology companies in the industry (Press release, Congruence Therapeutics, SEP 22, 2025, View Source [SID1234656143]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This recognition from Fierce Biotech serves as further validation of the impactful science we are undertaking to develop transformative medicines for significant unmet medical needs and underscores what matters most to us: the patients and families waiting for treatment options," commented Dr. Clarissa Desjardins, co-founder and CEO of Congruence. "We remain committed and laser-focused on advancing small molecule pharmacological drugs that have the potential to transform care for people affected by MC4R-driven genetic obesity, GBA-driven Parkinson’s disease, and α1-Antitrypsin-deficiency. This award strengthens our resolve to deliver these novel therapies to the bedside of those who need them most."
The Fierce 15 honor is intended to celebrate the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is Fierce Biotech’s 23rd annual Fierce 15 selection.
"Over the past 23 years, our Fierce 15 special report has spotlighted the private biotechs pushing science into uncharted territory, whose approaches and discoveries represent genuine leaps forward," said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare, "This year we’ve selected 15 pre-commercial biotechs that are advancing transformative science in an unrelenting industry landscape. These companies exemplify the innovation and determination driving the next generation of therapies that will hopefully benefit patients worldwide."
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.